Reconsidering Prostate Cancer Mortality - The Future of PSA Screening

N Engl J Med. 2020 Apr 16;382(16):1557-1563. doi: 10.1056/NEJMms1914228.

Authors

H Gilbert Welch¹, Peter C Albertsen¹

Affiliation

¹ From the Center for Surgery and Public Health, Brigham and Women's Hospital, Boston (H.G.W.); and the Division of Urology, Department of Surgery, University of Connecticut Health Center, Farmington (P.C.A.).

PMID: 32294352
DOI: 10.1056/NEJMms1914228

No abstract available

MeSH terms

Early Detection of Cancer* / adverse effects
Early Detection of Cancer* / methods
Humans
Incidence
Male
Medical Overuse / prevention & control
Mortality / trends
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / diagnosis
Prostatic Neoplasms / epidemiology
Prostatic Neoplasms / mortality*
Prostatic Neoplasms / therapy
Reference Values
United States / epidemiology

Substances

Prostate-Specific Antigen